CN115551850A - 半乳凝素-3的小分子抑制剂 - Google Patents
半乳凝素-3的小分子抑制剂 Download PDFInfo
- Publication number
- CN115551850A CN115551850A CN202180034243.5A CN202180034243A CN115551850A CN 115551850 A CN115551850 A CN 115551850A CN 202180034243 A CN202180034243 A CN 202180034243A CN 115551850 A CN115551850 A CN 115551850A
- Authority
- CN
- China
- Prior art keywords
- mmol
- diseases
- fluorophenyl
- alkyl
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022627P | 2020-05-11 | 2020-05-11 | |
| US63/022,627 | 2020-05-11 | ||
| PCT/US2021/031479 WO2021231243A1 (en) | 2020-05-11 | 2021-05-10 | Small molecule inhibitors of galectin-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115551850A true CN115551850A (zh) | 2022-12-30 |
Family
ID=76284161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180034243.5A Pending CN115551850A (zh) | 2020-05-11 | 2021-05-10 | 半乳凝素-3的小分子抑制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12286424B2 (https=) |
| EP (1) | EP4149939A1 (https=) |
| JP (1) | JP7677995B2 (https=) |
| KR (1) | KR20230009433A (https=) |
| CN (1) | CN115551850A (https=) |
| WO (1) | WO2021231243A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CA3000924A1 (en) | 2015-11-09 | 2017-05-18 | Galecto Biotech Ab | Novel galactoside inhibitors of galectins |
| KR20200015528A (ko) * | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| US12269819B2 (en) * | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
-
2021
- 2021-05-10 US US17/998,261 patent/US12286424B2/en active Active
- 2021-05-10 JP JP2022568549A patent/JP7677995B2/ja active Active
- 2021-05-10 WO PCT/US2021/031479 patent/WO2021231243A1/en not_active Ceased
- 2021-05-10 CN CN202180034243.5A patent/CN115551850A/zh active Pending
- 2021-05-10 EP EP21730348.6A patent/EP4149939A1/en active Pending
- 2021-05-10 KR KR1020227042914A patent/KR20230009433A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149939A1 (en) | 2023-03-22 |
| WO2021231243A1 (en) | 2021-11-18 |
| JP7677995B2 (ja) | 2025-05-15 |
| JP2023525527A (ja) | 2023-06-16 |
| KR20230009433A (ko) | 2023-01-17 |
| US12286424B2 (en) | 2025-04-29 |
| US20230212158A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102459272B (zh) | 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法 | |
| CN103562210B (zh) | 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法 | |
| CN112770745B (zh) | 用于治疗特定白血病的化合物 | |
| WO2023045960A1 (zh) | 一种吡啶类衍生物及其用途 | |
| CN112166114A (zh) | Brm靶向化合物和相关使用方法 | |
| WO2024153180A1 (zh) | 杂环类化合物、其药物组合物及其用途 | |
| CN109153643A (zh) | 取代的吲哚mcl-1抑制剂 | |
| TW201630907A (zh) | ＴＧＦβＲ拮抗劑 | |
| KR20220140710A (ko) | 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도 | |
| CN109689664B (zh) | 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物 | |
| WO2022111526A1 (zh) | 一种苯环衍生物及其组合物和药学上的应用 | |
| WO2024125532A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| WO2024067818A1 (zh) | 一种用于bcl-2蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 | |
| WO2023016521A1 (zh) | 取代三唑类衍生物、其制备方法、药物组合物和用途 | |
| WO2025167948A1 (zh) | 嘧啶并大环类kras抑制剂 | |
| CN113727988A (zh) | 半乳糖凝集素-3的小分子抑制剂 | |
| JP2021527102A (ja) | ガレクチン−３抑制剤を模したテトラヒドロピラン系チオ二糖類 | |
| WO2023217201A2 (zh) | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 | |
| TW202227452A (zh) | 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途 | |
| JP7677995B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| CN114980975A (zh) | 二氢环戊二烯并异喹啉磺酰胺衍生物 | |
| CN115135659A (zh) | 一类吗啉衍生物及其制备方法和应用 | |
| CN121443603A (zh) | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物 | |
| CN115551855A (zh) | 半乳凝素-3的小分子抑制剂 | |
| CN110167946A (zh) | 具有tnap抑制活性的磺酰胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |